Literature DB >> 30377273

Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition.

Masanori Kawakami1, Lisa Maria Mustachio1, Lin Zheng1, Yulong Chen1, Jaime Rodriguez-Canales2, Barbara Mino2, Jonathan M Kurie1, Jason Roszik3,4, Pamela Andrea Villalobos2, Kelsie L Thu5, Jennifer Silvester5, David W Cescon5,6, Ignacio I Wistuba2, Tak W Mak7,8, Xi Liu1, Ethan Dmitrovsky1,9,10.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30377273      PMCID： PMC6243257          DOI： 10.1073/pnas.1813967115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  6 in total

1.  The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.

Authors:  Peter B Sampson; Yong Liu; Bryan Forrest; Graham Cumming; Sze-Wan Li; Narendra Kumar Patel; Louise Edwards; Radoslaw Laufer; Miklos Feher; Fuqiang Ban; Donald E Awrey; Guodong Mao; Olga Plotnikova; Richard Hodgson; Irina Beletskaya; Jacqueline M Mason; Xunyi Luo; Vincent Nadeem; Xin Wei; Reza Kiarash; Brian Madeira; Ping Huang; Tak W Mak; Guohua Pan; Henry W Pauls
Journal:  J Med Chem       Date:  2015-01-08       Impact factor: 7.446

2.  CFI-400945 is not a selective cellular PLK4 inhibitor.

Authors:  Karen Oegema; Robert L Davis; Pablo Lara-Gonzalez; Arshad Desai; Andrew K Shiau
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-30       Impact factor: 11.205

3.  Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.

Authors:  Masanori Kawakami; Lisa Maria Mustachio; Lin Zheng; Yulong Chen; Jaime Rodriguez-Canales; Barbara Mino; Jonathan M Kurie; Jason Roszik; Pamela Andrea Villalobos; Kelsie L Thu; Jennifer Silvester; David W Cescon; Ignacio I Wistuba; Tak W Mak; Xi Liu; Ethan Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-06       Impact factor: 11.205

4.  Polo-like kinase 4 inhibition: a strategy for cancer therapy?

Authors:  Andrew J Holland; Don W Cleveland
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

5.  Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.

Authors:  Jacqueline M Mason; Dan Chi-Chia Lin; Xin Wei; Yi Che; Yi Yao; Reza Kiarash; David W Cescon; Graham C Fletcher; Donald E Awrey; Mark R Bray; Guohua Pan; Tak W Mak
Journal:  Cancer Cell       Date:  2014-07-17       Impact factor: 31.743

6.  Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4.

Authors:  Yao Liang Wong; John V Anzola; Robert L Davis; Michelle Yoon; Amir Motamedi; Ashley Kroll; Chanmee P Seo; Judy E Hsia; Sun K Kim; Jennifer W Mitchell; Brian J Mitchell; Arshad Desai; Timothy C Gahman; Andrew K Shiau; Karen Oegema
Journal:  Science       Date:  2015-04-30       Impact factor: 47.728
  6 in total
  2 in total

Review 1.  PLK4: a promising target for cancer therapy.

Authors:  Yi Zhao; Xin Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-06       Impact factor: 4.553

Review 2.  Keep Calm and Carry on with Extra Centrosomes.

Authors:  Batuhan Mert Kalkan; Selahattin Can Ozcan; Nicholas J Quintyne; Samantha L Reed; Ceyda Acilan
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.